oxazoles has been researched along with aleglitazar in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.69) | 29.6817 |
| 2010's | 33 (84.62) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Charbonnel, B | 1 |
| Chognot, C; Henry, RR; Herz, M; Lincoff, AM; Mudaliar, S; Rabbia, M | 1 |
| Banken, L; Jamois, C; Liogier D'ardhuy, X; Sanwald-Ducray, P | 1 |
| Cavender, MA; Lincoff, AM | 1 |
| Gaspari, F; Herz, M; Perico, N; Rabbia, M; Urbanowska, T; Viberti, G; Wieczorek Kirk, D | 1 |
| Lecka-Czernik, B | 1 |
| Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM | 1 |
| Bénardeau, A; Hansen, BC; Meyer, M; Mizrahi, J; Sebokova, E; Tigno, XT | 1 |
| Davis, SN; Uhl, L; Younk, LM | 1 |
| Bentley, D; Jordan, P; Ruf, T; Russell-Yarde, F; Sturm, S | 1 |
| Funk, C; Paehler, A; Ruf, T; Seiberling, M; Sturm, S; Weick, I | 1 |
| Wilding, JP | 1 |
| Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
| Blander, G; Bobadilla, M; Catlett, NL; Deehan, R; Edgar, A; Elliston, KO; Haefliger, C; Ladd, W; Maerz-Weiss, P; Mizrahi, J; Steiner, G; Wong, B; Wright, MB | 1 |
| Atzpodien, EA; Bénardeau, A; Funk, JM; Meyer, M; Mizrahi, J; Sebokova, E; Uhles, S; Verry, P; Winter, M; Wright, MB | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Banken, L; Jamois, C; Sanwald-Ducray, P | 1 |
| Böhm, M; Gensch, C; Laufs, U; Pavlickova, V; Pöss, J; Schirmer, SH; Werner, CM; Wright, MB | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
| Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D | 1 |
| Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Andjelkovic, M; Fischer, A; Gastaldelli, A; Heise, T; Herz, M; Nosek, L; Stirban, AO | 1 |
| Baradaran, B; Majidinia, M; Rameshknia, V; Samadi, N; Shafiei-Irannejad, V; Targhaze, N; Yousefi, B; Zarghami, N | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Nanhwan, MK; Qian, J; Ye, Y | 1 |
| Calabriso, N; Carluccio, MA; De Caterina, R; Massaro, M; Pellegrino, M; Scoditti, E; Storelli, C; Wabitsch, M; Wright, M | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Chen, Y; Nanhwan, MK; Qian, J; Ye, Y | 1 |
| Atzpodien, EA; Bopst, M | 1 |
| Cosentino, F; Grobbee, DE; Lincoff, AM; Mellbin, L; Morici, N; Nozza, A; Perrone Filardi, P; Ponticelli, C; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC | 1 |
| Cavallini, C; Cosentino, F; Eijkemans, MJ; Ferri, M; Grobbee, DE; Lambers Heerspink, HJ; Lincoff, AM; Malmberg, K; Morici, N; Morocutti, G; Murena, E; Nozza, A; Perrone Filardi, P; Ryden, L; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC; Toyama, T | 1 |
| Buse, JB; Grobbee, DE; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Hou, MC; Hsieh, YC; Huang, CC; Huang, SF; Huang, YH; Lee, KC; Li, TH; Lin, HC; Liu, RS; Tsai, HC; Yang, YY | 1 |
| Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB | 1 |
| Grobbee, DE; Heerspink, HJL; Koomen, JV; Lincoff, AM; Nicholls, SJ; Schrieks, IC; Schwartz, GG; Stevens, J; Svensson, A; Wedel, H; Weichert, A | 1 |
| Han, CL; Qu, CZ | 1 |
| Drosatos, K; Kalliora, C | 1 |
6 review(s) available for oxazoles and aleglitazar
| Article | Year |
|---|---|
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2010 |
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Topics: Apolipoproteins B; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Fibric Acids; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Triglycerides | 2011 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Thiophenes; Treatment Outcome; Weight Gain | 2020 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
18 trial(s) available for oxazoles and aleglitazar
| Article | Year |
|---|---|
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Topics: Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Safety; Single-Blind Method; Thiazolidinediones; Thiophenes; Treatment Outcome | 2009 |
Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Topics: Aged; Area Under Curve; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxazoles; Socioeconomic Factors; Thiophenes | 2010 |
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oxazoles; Prognosis; Renal Insufficiency; Retrospective Studies; Thiophenes; Young Adult | 2011 |
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Topics: Adolescent; Adult; Aged; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thiophenes; Young Adult | 2011 |
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Topics: Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Oxazoles; PPAR alpha; PPAR gamma; Quinolines; Thiophenes; Time Factors; Young Adult | 2012 |
Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Topics: Adult; Aged; Carbon Radioisotopes; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2012 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Topics: Anticoagulants; Area Under Curve; Cross-Over Studies; Drug Interactions; Factor VII; Humans; Male; Oxazoles; PPAR alpha; PPAR gamma; Prothrombin Time; Stereoisomerism; Thiophenes; Warfarin; Young Adult | 2014 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes | 2014 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Thiophenes | 2015 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipid Metabolism; Metabolic Syndrome; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes; Treatment Outcome | 2016 |
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Analysis of Variance; Biomarkers; Cause of Death; Comorbidity; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Oxazoles; Patient Discharge; Percutaneous Coronary Intervention; Peroxisome Proliferator-Activated Receptors; Predictive Value of Tests; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Thiophenes | 2017 |
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Revascularization; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome | 2018 |
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Thiophenes | 2018 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2020 |
15 other study(ies) available for oxazoles and aleglitazar
| Article | Year |
|---|---|
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2010 |
Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Eating; Glycated Hemoglobin; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Macaca mulatta; Male; Metabolic Syndrome; Obesity; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Thiophenes; Time Factors; Triglycerides; Weight Loss | 2011 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |
Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Topics: Alkanesulfonates; Cells, Cultured; Fenofibrate; Hepatocytes; Humans; Oxazoles; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes | 2012 |
Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Topics: Animals; Blood Glucose; Cataract; Diabetic Nephropathies; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Thiophenes | 2013 |
The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Case-Control Studies; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Artery Disease; Disease Models, Animal; Endothelial Cells; Hindlimb; Humans; Ischemia; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; PPAR gamma; Signal Transduction; Stem Cells; Thiophenes | 2014 |
Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Chromans; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Fenofibrate; Gene Expression; Humans; K562 Cells; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rhodamine 123; Signal Transduction; Thiazolidinediones; Thiophenes; Troglitazone | 2015 |
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cardiovascular Agents; Cell Survival; Diabetes Mellitus, Experimental; Heart; Humans; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxazoles; PPAR alpha; PPAR gamma; Protective Agents; Signal Transduction; Thiophenes | 2016 |
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Topics: Adipocytes; Adiponectin; Cell Line; Cell Movement; Cell Survival; Chemokine CCL2; Chemokine CXCL10; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Lipid Metabolism; Oxazoles; p38 Mitogen-Activated Protein Kinases; PPAR alpha; PPAR gamma; Thiophenes; Tumor Necrosis Factor-alpha | 2016 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Topics: Animals; Apoptosis; Caspase 3; Cell Survival; Cells, Cultured; Cytochromes c; Cytoprotection; Dose-Response Relationship, Drug; Genotype; Hyperglycemia; Hypoglycemic Agents; Mice, Knockout; Myocytes, Cardiac; Oxazoles; Oxidative Stress; Phenotype; PPAR alpha; PPAR gamma; RNA Interference; Signal Transduction; Thiophenes; Time Factors; Transfection | 2017 |
Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Topics: Animals; Carcinogenicity Tests; Cricetinae; Humans; Macaca fascicularis; Mice; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Risk Assessment; Thiophenes; Toxicity Tests | 2017 |
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Topics: Animals; Caco-2 Cells; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Neovascularization, Pathologic; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Splanchnic Circulation; Thiophenes | 2018 |
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes | 2019 |